Skip to main content

Can-Fite BioPharma Ltd.

CANF
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001536196

No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.

Holders of 5% or more of CANF

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Can-Fite BioPharma Ltd., largest stake first. The change is against the holder's previous filing.

No holder currently reports owning 5% or more of Can-Fite BioPharma Ltd. on Schedule 13D or 13G.

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

3 Schedule 13D and 13G filings on Can-Fite BioPharma Ltd., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on CANF
Filed (ET)FilerFormStakeChangeEvent dateFiling
Apr 23, 20254:30 PM ETOrca Capital AG13G/A4.10%157.4M shares−5.60 ppfrom 9.70%Below 5%Apr 22, 2025SEC
Apr 16, 20254:30 PM ETOrca Capital AG13G9.70%375.0M sharesNewApr 14, 2025SEC
Feb 14, 20255:33 PM ETArmistice Capital, LLCand 1 other13G/A4.99%440.4K shares–Below 5%Dec 31, 2024SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Can-Fite BioPharma Ltd. shares.

No Form 144 notices for Can-Fite BioPharma Ltd. are on file.